Collegium Pharmaceutical (COLL) saw its stock surge 5.82% in pre-market trading on Thursday, following the release of its impressive second-quarter results and optimistic full-year guidance. The pharmaceutical company's performance exceeded analyst expectations, driving investor confidence.

For the second quarter, Collegium reported adjusted earnings per share of $1.68, beating the analyst consensus estimate of $1.66 by 1.27%. This represents a 3.7% increase from the same period last year. Revenue for the quarter came in at $188 million, surpassing the analyst estimate of $180.9 million and marking a substantial 29.41% year-over-year growth.

Adding to the positive sentiment, Collegium provided an upbeat outlook for the full fiscal year. The company expects revenue in the range of $745-760 million and adjusted EBITDA between $440-455 million. Furthermore, Collegium's board of directors authorized a $150 million share repurchase program, signaling confidence in the company's financial position and future prospects.